GILEAD SCIENCES, INC. Investment Income, Nonoperating
GILEAD SCIENCES, INC. (GILD) reported Investment Income, Nonoperating of $45.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-08-06
- GILEAD SCIENCES, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $45.00M, a 38.36% decline year-over-year.
- GILEAD SCIENCES, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $95.00M, a 1.06% increase year-over-year.
- GILEAD SCIENCES, INC. investment income, nonoperating for the quarter ending 2025-12-31 was $95.00M, a 11.76% increase year-over-year.
- GILEAD SCIENCES, INC. investment income, nonoperating for the quarter ending 2025-09-30 was $88.00M, a 69.23% increase year-over-year.
- GILEAD SCIENCES, INC. investment income, nonoperating for fiscal 2025 was $349.00M, a 24.20% increase from fiscal 2024.
- GILEAD SCIENCES, INC. investment income, nonoperating for fiscal 2024 was $281.00M, a 25.27% decline from fiscal 2023.
- GILEAD SCIENCES, INC. investment income, nonoperating for fiscal 2023 was $376.00M, a 254.72% increase from fiscal 2022.
- GILEAD SCIENCES, INC. investment income, nonoperating for fiscal 2022 was $106.00M.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.00M 10-Q · filed 2026-08-06 | $140.00M 10-Q · filed 2026-08-06 | $235.00M derived: sum of 3 quarters · filed 2026-08-06 | $323.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $95.00M 10-Q · filed 2026-05-07 | $190.00M derived: sum of 2 quarters · filed 2026-05-07 | $278.00M derived: sum of 3 quarters · filed 2026-05-07 | $351.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $95.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $183.00M derived: sum of 2 quarters · filed 2026-02-24 | $256.00M derived: sum of 3 quarters · filed 2026-08-06 | $349.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $88.00M 10-Q · filed 2025-11-07 | $161.00M derived: sum of 2 quarters · filed 2026-08-06 | $254.00M 10-Q · filed 2025-11-07 | $340.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $73.00M 10-Q · filed 2026-08-06 | $166.00M 10-Q · filed 2026-08-06 | $252.00M derived: sum of 3 quarters · filed 2026-08-06 | $304.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $94.00M 10-Q · filed 2026-05-07 | $179.00M derived: sum of 2 quarters · filed 2026-05-07 | $231.00M derived: sum of 3 quarters · filed 2026-05-07 | $266.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $85.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $137.00M derived: sum of 2 quarters · filed 2026-02-24 | $172.00M derived: sum of 3 quarters · filed 2026-02-24 | $281.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $52.00M 10-Q · filed 2025-11-07 | $87.00M derived: sum of 2 quarters · filed 2025-11-07 | $196.00M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $35.00M 10-Q · filed 2025-08-07 | $144.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $108.00M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $376.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $106.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |